leadf
logo-loader
viewLexaria Bioscience Corp.

Full interview: Lexaria Bio Science working with frontline companies to battle COVID-19

Lexaria Bioscience (CSE:LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive in Vancouver to discuss the company commencing a program, in collaboration with leading laboratories in Canada and the U.S. to study the benefits of DehydraTECH  in the fight against coronavirus disease COVID-19.

Bunka telling Proactive about that technology and why it may be effective, in the way it delivers fat-soluble drugs into the bloodstream.

Quick facts: Lexaria Bioscience Corp.

Price: 0.235 CAD

CSE:LXX
Market: CSE
Market Cap: $21.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Lexaria receives ethics board ok to launch human study with DehydraTech for...

Lexaria Bioscience (CSE: LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive with news the company has received ethics board approval to conduct a pilot human pharmacokinetic exploratory study of antiviral drugs that have previously been studied against other coronavirus...

3 weeks ago

2 min read